Papaverine
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Papaverine: From Vascular Spasm to Ischemic Disease
One-Sentence Summary
Papaverine is an opium-alkaloid smooth-muscle relaxant/vasodilator, historically used off-label for vascular and visceral spasm (e.g., cerebral, coronary, and mesenteric vasospasm) and as an intracavernosal agent for erectile dysfunction. The TxGNN model predicts it may be effective for Ischemic Disease, with 4 clinical trials and 20 publications currently associated with this direction — though none of the trials test papaverine as the direct intervention. India regulatory filing data is not on record (drug not currently marketed in India).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vasodilator for vascular/visceral smooth-muscle spasm (cerebral, coronary, mesenteric vasospasm); no India-specific approved-indication text on file |
| Predicted New Indication | Ischemic disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L3 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed DrugBank-level MOA data for papaverine is not available in this evidence pack. Based on established pharmacological knowledge, papaverine is a non-selective phosphodiesterase (PDE3/4/10) inhibitor that raises intracellular cAMP/cGMP in vascular smooth muscle cells, producing direct, neurogenically-independent vasodilation. This mechanism underlies its long-standing, well-documented off-label clinical uses: intra-arterial infusion for non-occlusive mesenteric ischemia (NOMI), intracoronary administration to measure coronary flow reserve, and treatment of cerebral/intraoperative arterial vasospasm.
Ischemic disease, at its core, reflects inadequate blood flow to tissue — frequently driven or worsened by vasospasm and reduced microvascular flow reserve. Papaverine’s direct smooth-muscle relaxant action is mechanistically well-matched to this pathophysiology, which is consistent with why the TxGNN model surfaces this link with a very high score.
However, the supporting evidence base is largely historical and diagnostic/procedural rather than therapeutic-outcome focused: papaverine has long been used as a pharmacologic tool (e.g., intracoronary papaverine for flow-reserve measurement, topical papaverine to prevent arterial spasm during CABG) rather than as a treatment studied in modern controlled trials for ischemic disease as a defined indication. The mechanistic plausibility is strong, but clinical trial evidence remains indirect.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05562908 | N/A | Completed | 165 | Compares skeletonised vs. pedicled internal thoracic artery harvesting for CABG; papaverine is a common intraoperative vasodilator in this setting but is not the trial’s tested intervention |
| NCT06125392 | N/A | Recruiting | 1000 | Multicenter registry characterizing chronic angina without obstructive coronary stenosis and coronary microvascular/spasm dysfunction; observational, does not test papaverine |
| NCT06014242 | N/A | Withdrawn | 0 | Intended to study peripheral microvascular resistance as a predictor of limb salvage in critical limb ischemia; withdrawn before enrollment, not a papaverine intervention study |
| NCT06795035 | N/A | Recruiting | 70 | Observational assessment of coronary microvascular dysfunction after STEMI using continuous saline thermodilution; does not test papaverine |
Note: None of the identified trials use papaverine as the study intervention — all four were graded “C” relevance (indirect/disease-area match only) in the evidence pack.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3661361 | 1987 | Cohort | American Heart Journal | Intracoronary papaverine found superior to radiographic contrast for measuring coronary flow reserve in patients with ischemic heart disease |
| 32478401 | 2020 | Cohort | Urology Journal | Identifies predictive factors for ischemic priapism following intracavernosal papaverine injection (467 patients) |
| 831413 | 1977 | Experimental | American Heart Journal | Papaverine and adenosine vasodilator infusion studied in coronary reperfusion; both affect post-reperfusion myocardial blood flow gradients |
| 32713799 | 2020 | Animal/Mechanistic | Journal of Pharmacological Sciences | Papaverine significantly reduced ischemic infarct volume in a mouse cerebral ischemia-reperfusion model via anti-inflammatory/immunomodulatory pathways |
| 8293164 | 1993 | Review | Current Opinion in Neurology | Reviews interventional neuroradiology techniques including superselective papaverine infusion for cerebral vasospasm after aneurysm rupture |
| 7590571 | 1995 | Review | Hepato-Gastroenterology | Reviews non-occlusive mesenteric ischemia pathophysiology and management, including vasodilator (papaverine) infusion therapy |
| 12964071 | 2003 | Review | RöFo | Reviews non-occlusive mesenteric ischemia diagnosis and treatment, noting intra-arterial papaverine as a therapeutic option |
| 11341865 | 2001 | Review | Current Treatment Options in Cardiovascular Medicine | Reviews mesenteric vascular disease management, including pharmacologic/endovascular vasodilator approaches |
| 16368347 | 2006 | Experimental | The Annals of Thoracic Surgery | Compares papaverine vs. glyceryl-nitrate/verapamil solution for treating internal thoracic artery spasm during CABG |
| 9674923 | 1998 | Experimental | Microsurgery | In vitro/in vivo rabbit carotid artery study of lidocaine and papaverine vasodilatory effects relevant to flap ischemia |
Safety Considerations
Drug Interactions: DrugBank/DDInter records 238 total interactions for papaverine. Selected Major-level interactions include: Abiraterone, Tramadol, Adenosine, Salbutamol, Alfuzosin, Amiodarone, Amisulpride, Amitriptyline, Anagrelide, Propofol, Loperamide, Apalutamide, Apomorphine, Arsenic trioxide, Lumefantrine, Asenapine, and Atomoxetine. Moderate-level interactions include Amifostine and Apraclonidine. Given the volume and severity of these interactions, a full interaction screen against the patient’s concurrent medications is required before use.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link between papaverine’s vasodilatory action and ischemic disease pathophysiology is strong, and its use as a vasodilator in ischemia-adjacent procedural/diagnostic settings (coronary flow reserve measurement, mesenteric ischemia, CABG graft spasm) is well established. However, no identified trial tests papaverine as a therapeutic intervention specifically for an “ischemic disease” endpoint, and evidence level remains L3 (observational/mechanistic, no RCT).
To proceed, the following is needed:
- Official India-market prescribing information (warnings, contraindications) — currently unavailable (drug not marketed in India)
- Confirmed original/approved indication text from a regulatory source
- Detailed DrugBank MOA record to formally substantiate the mechanistic rationale
- A prospective or controlled study evaluating papaverine specifically for an ischemic-disease clinical endpoint, rather than as a procedural/diagnostic vasodilator
- Full DDI review against target-population concurrent medications given the high volume of Major-level interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.